Could stroke treatment window be extended? new study investigates

NCT ID NCT07419997

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking back at medical records of 2,600 stroke patients who received clot-busting drugs between 4.5 and 24 hours after their stroke started. The goal is to see if giving the drug later than the usual 4.5-hour window can still lead to good recovery. The study does not test a new treatment but gathers information to guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could show that giving clot-busting drugs later than currently recommended may help some stroke patients recover better.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other factors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xuanwu Hospital Capital Medical University, Beijing, Beijing 100053

    RECRUITING

    Beijing, 100053, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••